Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line

Citations Over TimeTop 1% of 2008 papers

Abstract

Epigenetic reprogramming is commonly observed in cancer, and is hypothesized to involve multiple mechanisms, including DNA methylation and Polycomb repressive complexes (PRCs). Here we devise a new experimental and analytical strategy using customized high-density tiling arrays to investigate coordinated patterns of gene expression, DNA methylation, and Polycomb marks which differentiate prostate cancer cells from their normal counterparts. Three major changes in the epigenomic landscape distinguish the two cell types. Developmentally significant genes containing CpG islands which are silenced by PRCs in the normal cells acquire DNA methylation silencing and lose their PRC marks (epigenetic switching). Because these genes are normally silent this switch does not cause de novo repression but might significantly reduce epigenetic plasticity. Two other groups of genes are silenced by either de novo DNA methylation without PRC occupancy (5mC reprogramming) or by de novo PRC occupancy without DNA methylation (PRC reprogramming). Our data suggest that the two silencing mechanisms act in parallel to reprogram the cancer epigenome and that DNA hypermethylation may replace Polycomb-based repression near key regulatory genes, possibly reducing their regulatory plasticity.

Related Papers

• → Epigenetic alterations induced by environmental stress associated with metabolic and neurodevelopmental disorders(2016)33 cited
• → Epidrugs: Toward Understanding and Treating Diverse Diseases(2022)8 cited
• → Community Resources and Technologies Developed Through the NIH Roadmap Epigenomics Program(2014)12 cited
• → Entering the post-epigenomic age: back to epigenetics(2018)10 cited
• [The epigenome in neurological disorders: a new marker for understanding neuronal dysfunction].(2014)